Nouscom secures $135M Series D to advance cancer vaccine
Nouscom has closed an oversubscribed Series D financing worth $135 million. The clinical-stage cancer company plans to use the funds to move its main vaccine candidate into a Phase 2 trial. Nouscom said it is enthusiastic about the program's potential.
Cancer vaccine development sits within the broader field of oncology research, where clinical-stage companies test experimental treatments in successive trial phases. Nouscom's $135 million Series D, described as oversubscribed, is meant to move its lead vaccine candidate into a Phase 2 study. The company said it is optimistic about the program's potential.
If the Phase 2 trial proceeds, patients with cancer could eventually have another experimental option to consider, though success is uncertain. The funding may strengthen Nouscom's ability to conduct research and could draw attention to cancer vaccine development more broadly. Investors and researchers may see the oversubscribed round as a signal of interest in the sector, but clinical outcomes will determine real-world benefit.